Roivant Sciences Ltd. (NASDAQ:ROIV) Position Lifted by WINTON GROUP Ltd

WINTON GROUP Ltd raised its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 92,526 shares of the company’s stock after purchasing an additional 1,332 shares during the period. WINTON GROUP Ltd’s holdings in Roivant Sciences were worth $1,095,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC increased its holdings in Roivant Sciences by 57.0% in the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after buying an additional 1,288 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Roivant Sciences by 27.0% in the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares during the last quarter. Quarry LP raised its position in shares of Roivant Sciences by 50.0% during the 3rd quarter. Quarry LP now owns 7,500 shares of the company’s stock valued at $87,000 after acquiring an additional 2,500 shares in the last quarter. Blue Trust Inc. lifted its stake in Roivant Sciences by 550.1% during the fourth quarter. Blue Trust Inc. now owns 7,879 shares of the company’s stock worth $91,000 after purchasing an additional 6,667 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new position in Roivant Sciences in the fourth quarter worth $121,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

ROIV stock opened at $10.38 on Friday. Roivant Sciences Ltd. has a 1 year low of $9.96 and a 1 year high of $13.06. The stock has a market capitalization of $7.41 billion, a price-to-earnings ratio of -69.20 and a beta of 1.26. The stock’s fifty day moving average is $10.74 and its two-hundred day moving average is $11.41.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ROIV. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $17.10.

Insider Activity

In other Roivant Sciences news, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the stock in a transaction dated Monday, January 13th. The shares were bought at an average cost of $20.00 per share, with a total value of $336,900,200.00. Following the completion of the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eric Venker sold 434,478 shares of the company’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96. Following the completion of the sale, the chief operating officer now directly owns 1,127,290 shares of the company’s stock, valued at $12,197,277.80. The trade was a 27.82 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,573,245 shares of company stock valued at $17,079,242. Insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.